Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
ONX-0914 (PR-957) and Hippocampal Plasticity
2026-10-01
The reference study shows that chronic inhibition of non-constitutive proteasomes affects tetanus-evoked, but not theta-burst-evoked, hippocampal LTP in mice. Its combination of pathway-selective pharmacology, ex vivo electrophysiology, and hippocampal gene-expression analysis provides a framework for studying how proteasome subtypes contribute to synaptic plasticity.
Bortezomib (PS-341): Proteasome Research Guide
2026-09-30
Bortezomib, also called PS-341, is a reversible 20S proteasome inhibitor used in multiple myeloma research, mantle cell lymphoma research, and apoptosis assays. Its boronic acid pharmacophore enables proteasome inhibition, while cell-line and xenograft data provide model-specific research benchmarks rather than universal potency predictions.
Troglitazone in PPARγ Agonist TAM Assays
2026-09-30
Troglitazone provides a practical PPARγ agonist tool for connecting lipid and glucose metabolism studies with macrophage and renal carcinoma experiments. This guide shows how to use it as a controlled pathway perturbation, distinguish SPP1-related phenotype changes from nonspecific toxicity, and build reproducible translational assays.
MLN8237 (Alisertib): Assay Workflow Guide
2026-09-29
This scenario-driven guide explains how MLN8237 (Alisertib), SKU A4110, can support interpretable Aurora A inhibition, viability, proliferation, and apoptosis experiments. It covers formulation, dose design, orthogonal validation, cross-domain limitations, and practical vendor-selection criteria.
Sodium Orthovanadate in Insulin Signaling Assays
2026-09-29
Sodium Orthovanadate is more than a phosphorylation-preserving reagent: it can separate true cellular signaling from post-lysis signal drift. This guide connects Na3VO4 chemistry with adipocyte insulin-signaling readouts, assay controls, and practical workflow decisions.
NU6300 Targets GSDMD Cys191 to Block Pyroptosis
2026-09-28
The reference study identifies NU6300 as a covalent GSDMD inhibitor that reacts with cysteine-191 and interferes with cleavage, palmitoylation, membrane localization, and oligomerization. Its pathway-dependent effects in inflammasome models, together with activity in colitis and sepsis models, provide a mechanistic framework for developing pyroptosis-directed anti-inflammatory compounds.
5-Azacytidine Triggers DNA Damage in Myeloma
2026-09-28
A preclinical study found that 5-azacytidine induces ATR-associated DNA damage responses and apoptosis in multiple myeloma cells, including therapy-resistant models. Its reported activity and synergy with doxorubicin or bortezomib support further investigation, while the in vitro evidence does not establish clinical benefit.
LG 101506: RXR Modulator Workflows in TNBC
2026-09-27
Use LG 101506 to test whether RXR modulation changes cellular phenotypes in cancer and metabolism models—not to assume a proven effect on PD-L1. This workflow pairs controlled compound handling with orthogonal RXR, checkpoint, and immune-cell readouts, while separating established TNBC findings from new hypotheses.
Topotecan HCl: Practical Assay Design
2026-09-26
A scenario-driven guide to using Topotecan HCl (SKU B2296) in viability, proliferation, and cytotoxicity workflows. It covers mechanism, concentration and solvent planning, interpretation limits, and practical criteria for selecting a supplier without overstating what the available data establish.
MLN2238: Mapping Proteasome Stress Signaling
2026-09-25
Explore how MLN2238, a potent proteasome β5 subunit inhibitor, can reveal the signaling response to proteotoxic stress. This article connects proteasome perturbation with ROS–JNK–CREB biology while distinguishing established findings from practical assay hypotheses.
Spectrophotometric Assays for Alfuzosin–Tadalafil
2026-09-25
Alqahtani and colleagues developed the first reported spectrophotometric methods for quantifying alfuzosin hydrochloride and tadalafil together in a binary mixture. Their absorbance-subtraction and ratio-difference approaches address overlapping spectra and were validated for tablet analysis, offering simpler alternatives to more instrument-intensive assays without establishing clinical or pharmacological effects.
BKT140 (BL-8040) in CXCR4 Oncology Workflows
2026-09-24
Build functional CXCR4 studies around BKT140 (BL-8040): connect receptor expression with chemotaxis, survival, and cell-mobilization readouts. Practical starting conditions and troubleshooting guidance help distinguish target engagement from assay artifacts while keeping imaging evidence in its proper translational context.
DMXAA and the Endothelial Logic of Tumor Control
2026-09-24
DMXAA (Vadimezan) offers a way to interrogate tumor-vessel injury, angiogenic signaling, and cell-death responses. Here, we connect its reported pharmacology to new evidence on endothelial STING-JAK1 biology—while keeping the evidence boundaries clear for translational study design.
MLN2238: From Proteasome Blockade to Stress Signaling
2026-09-23
Explore MLN2238 as a proteasome β5 subunit inhibitor and a tool for studying how proteotoxic stress reshapes cellular signaling. This article connects its target profile with CRTC–CREB findings and practical assay choices, while distinguishing established evidence from cross-model hypotheses.
MLN2238: From β5 Selectivity to Stress Signals
2026-09-23
MLN2238 is a proteasome β5 subunit inhibitor that enables researchers to connect catalytic-site inhibition with ROS, JNK, CREB, and proteostasis outcomes. This article presents a layered assay strategy for distinguishing direct proteasome effects from adaptive stress signaling in oncology and protein-aggregation models.
8664 records 6/578 page Previous Next First page 上5页 678910 下5页 Last page